CLVT
T2Clarivate Plc
Loading chart…
OverviewClarivate Plc provides information services and analytics for scientific research and intellectual property. Its Web of Science suite aids academia, while Derwe
Clarivate Plc provides information services and analytics for scientific research and intellectual property. Its Web of Science suite aids academia, while Derwent supports IP management. The company is divesting its Life Sciences & Healthcare segment, sharpening its focus on Academia & Government and Intellectual Property. Post-divestiture, around 92% of revenue will be recurring subscriptions, serving global academic, government, and R&D clients with AI-driven solutions.
- What They Do (Plain English & Analogies)
- Clarivate acts like a specialized intelligence agency for researchers, innovators, and businesses. They collect, organize, and analyze vast amounts of information, ranging from scientific papers and academic journals to patents and trademarks. They then provide smart tools and insights to help universities understand their research impact, scientists discover new breakthroughs, companies protect their inventions and brands, and pharmaceutical firms develop new medicines. Essentially, they provide the essential maps, compasses, and intelligence reports for anyone navigating the complex worlds of science, intellectual property, and innovation.
- Very Brief History
- Clarivate Plc, initially known as Clarivate Analytics Plc, was formed in 2016 following the acquisition of Thomson Reuters' Intellectual Property and Science business by Onex Corporation and Baring Private Equity Asia. The company rebranded to Clarivate Plc in May 2020. Since its formation, Clarivate has expanded through significant acquisitions, including Decision Resources Group and CPA Global in 2020, and ProQuest in 2021. In May 2019, Clarivate became publicly listed on the New York Stock Exchange (NYSE) through a merger with Churchill Capital Corp SPAC.
- "Street Stereotype"
- Clarivate is generally perceived on the street as a key "data owner" in the education, research, scientific knowledge, and intellectual property domains. Investors likely see it as a company with valuable proprietary data assets and workflow tools, particularly in academic publishing, citation analysis, patent search, and trademark management. The current focus is on its Value Creation Plan, shift to a subscription-first model, leveraging AI to drive efficiency and growth, and the strategic divestiture of its Life Science & Healthcare business.
- Subsidiaries On Linked In*
- ProQuest — Part of Clarivate; LinkedIn: proquest
- Web of Science Group — A Clarivate company; LinkedIn: web-of-science-group
- Derwent — A Clarivate company; LinkedIn: derwent-a-clarivate-company
- Cortellis — A Clarivate solution; LinkedIn: cortellis-a-clarivate-solution
- CompuMark — A Clarivate company; LinkedIn: compumark
- MarkMonitor — A Clarivate company; LinkedIn: markmonitor
- Customer Sectors & Example Clients
- Clarivate's diverse clientele spans government agencies, academic institutions, life science enterprises (including pharmaceutical and biotechnology companies), research and development corporations, and legal firms. Specific clients mentioned include Fuyao University in China, national IP offices such as the U.S. PTO (United States Patent and Trademark Office), and a new top 20 global pharmaceutical customer for its DRG Fusion platform. They also serve biotech companies for OpEx.
- New Customers / Segments They'Re Targeting
- Clarivate is targeting customers who want to embed their proprietary intelligence into their own corporate AI products and workflows, particularly larger customers. They are also expanding their reach by integrating their content with generic Large Language Models (LLMs) like ChatGPT and Claude through products like Nexus Connect, aiming to embed Clarivate proprietary intelligence into existing research workflows for the academic community. This is leading to new revenue streams.
- Supply Chain And Sourcing Geographies
- As an information services and analytics company, Clarivate's 'supply chain' primarily involves data acquisition, processing, and software development, which are intellectual rather than physical. The provided transcript and company description do not contain specific details about Clarivate's physical supply chain or sourcing geographies for products and components. Therefore, specific geographic sourcing for physical components is not applicable or disclosed.
- Sales Geographies And Expansion Plans
- Clarivate currently operates across the Americas, Middle East, Africa, Europe, and Asia Pacific regions. Management has indicated plans to expand sales into new geographies, specifically highlighting their efforts to expand their footprint in China, where they see significant momentum for their Academia & Government and Intellectual Property segments. They also launched Web of Science Research Intelligence globally.
- How Key Themes May Help/Hurt
- Clarivate, as a dominant player in Intellectual Property (IP) and trademark law, is well-positioned to benefit from the "Software '26: Legal Tech" theme. The accelerated AI integration and monetization within legal tech can help Clarivate by driving adoption of its new AI-powered products like IP-1 and RiskMark, which leverage proprietary data to enhance efficiency in IP workflows. The increasing demand for "fiduciary-grade AI" and compliance solutions, driven by regulatory complexity (e.g., EU AI Act, US state-level AI regulations), further strengthens Clarivate's position, as its curated proprietary content provides a crucial moat against generic LLMs. However, the theme also presents risks, such as slower-than-anticipated AI adoption by conservative legal firms due to "AI anxiety" and change management challenges, which could extend sales cycles. Intensifying competition from generic LLMs and AI startups could also challenge Clarivate's differentiation and pricing power, requiring continuous innovation. Macroeconomic headwinds could lead to cautious client spending on new, transformative legal tech solutions.
3 Main Long-Term Bull Details
- Effective Value Creation Plan & Subscription-First Strategy: Clarivate is consistently executing its Value Creation Plan, driving improved financial performance with accelerating organic subscription revenue growth and a higher recurring revenue mix (expected to be ~92% pro forma after divestiture). This strategy enhances predictability, retention, and cash-flow visibility.
- Strategic AI Innovation and Proprietary Data: Clarivate is intensifying investment in AI, leveraging its highly curated proprietary datasets built over decades. New AI-powered solutions like Web of Science Research Intelligence, Nexus Connect, and IP-1 are creating new revenue streams, deepening customer value, and reinforcing its competitive position.
- Focused Portfolio & Aggressive Debt Reduction: The divestiture of the Life Sciences & Healthcare segment creates a more focused company, allowing for targeted investments in its higher-growth Academia & Government and Intellectual Property segments. The planned use of net proceeds to reduce debt strengthens the balance sheet and enhances financial flexibility, enabling further shareholder value creation.
3 Main Long-Term Bear Details
- Headwinds in Transactional Revenues: Clarivate continues to face declines in transactional revenues, which partially offset recurring revenue growth. While partly due to a strategic shift to subscriptions, lumpiness in certain areas and potential broader market softness in non-subscription areas could temper overall revenue growth and create volatility.
- Execution Risk of LS&H Divestiture and AI Adoption: While strategic, the ongoing divestiture of the Life Sciences & Healthcare business carries execution risk, including timing and regulatory approvals. Additionally, despite AI innovation, the pace of competitive AI development and customer adoption of Clarivate's specific AI solutions in an evolving ecosystem where customers consume AI through various LLMs could challenge differentiation and growth acceleration.
- Foreign Exchange and Working Capital Impacts: The company has experienced adjusted EBITDA headwinds due to foreign exchange impacts. Higher working capital requirements due to the timing of receipts and disbursements have also impacted free cash flow, which is expected to be at the low end of the range due to transaction and restructuring costs.
- Competitors And Differentiation
- Clarivate's competitors include RELX, Thomson Reuters, IHS Markit, FactSet, Gartner, and Moody's. Clarivate differentiates itself by its ability to apply AI to highly curated proprietary datasets that have been built and refined over decades. They focus on providing agentic AI capabilities to efficiently solve complex workflow challenges across the entire IP lifecycle with products like IP-1. Their IP business has meaningful differentiators such as scale, trusted relationships with leading law firms and blue-chip corporate IP teams, a strong recurring annuity and renewal engine, and differentiated proprietary content. They are also recognized as an AI innovator in the academic ecosystem.
- Recent Performance & What The Market'S Focused On
- Clarivate reported Q2 2026 revenue of $587 million, a 5.5% decrease year-over-year, with organic revenues declining 1.5% due to lower transactional revenues, partially offset by 0.7% organic subscription growth. The company reported a net loss of $269 million, primarily driven by a non-cash impairment charge related to the divestiture of the Life Sciences & Healthcare segment. Adjusted diluted EPS was $0.19, beating analyst forecasts. Organic ACV growth improved to 1.5%, and profit margin expanded to over 42%. The market is focused on Clarivate's ability to accelerate organic growth, particularly recurring revenue, in the second half of 2026 and into 2027. Key areas of market focus include the successful closing of the Life Sciences & Healthcare divestiture and the subsequent debt reduction, the continued expansion of adjusted EBITDA margin, and the generation of strong free cash flow. Investors are also closely watching the performance of new AI-driven products and the return to growth in the Intellectual Property segment.
- Revenue Segments And Estimated Mix
- Academia & Government (A&G) — Mix: Significant segment; Source: Transcript Q2 2026; Trend: Delivered 2% organic ACV growth in Q2 2026. Expected to approach 3% organic ACV growth by year-end. Focus on subscription revenue and AI-native platforms like Web of Science Research Intelligence and Nexus Connect. Recurring revenue mix for the company is expected to be approximately 92% pro forma after LS&H divestiture.
- Intellectual Property (IP) — Mix: Significant segment; Source: Transcript Q2 2026; Trend: Recurring organic revenue improved to flat in Q2 2026. Expected to return to growth in the second half of 2026. Focus on retention across annuities and software, increased commercial intensity, and accelerating AI innovation with products like IP-1 and RiskMark.
- Life Sciences & Healthcare (LS&H) — Mix: Significant segment, highest proportion of transactional revenue; divested; Source: Transcript Q2 2026; Trend: Delivered 2% organic ACV growth in Q2 2026. Agreement to sell this segment announced in early July 2026 to Altaris. Expected to close by year-end 2026. This divestiture will increase the company's pro forma recurring revenue mix from 89% to approximately 92%.
- Product Brands
- Web of Science
- InCites
- Journal Citation Reports
- EndNote
- ScholarOne
- Converis
- Publons
- Kopernio
- Cortellis
- Newport Integrity
- Derwent Innovation
- Techstreet
- IP Professional Services
- CompuMark
- MarkMonitor
- DRG Fusion
- OpEx
- Brand Image Search
- Clarivate Academic AI solutions
- Nexus Connect
- Alma Specto
- Web of Science Research Intelligence
- IP-1
- RiskMark
- Ex Libris
- Innovative
- IPfolio
- Primo
- Leganto
- Vega
Bull / Bear DetailsClarivate, a leading information services and analytics firm, is effectively executing its Value Creation Plan, driving sequential improvement in recurring orga
Thesis
Clarivate, a leading information services and analytics firm, is effectively executing its Value Creation Plan, driving sequential improvement in recurring organic growth and significant adjusted EBITDA margin expansion. Strategic AI innovation across its core Academia & Government and Intellectual Property segments, coupled with the agreed divestiture of its Life Sciences & Healthcare business and aggressive debt reduction, positions the company for enhanced focus and long-term shareholder value creation. (Updated: 2026-08-06)
Bull case
Clarivate's Value Creation Plan is delivering, with Q2 2026 organic ACV growth improving to 1.5% and profit margin expanding to over 42%. The company expects sequential improvement in recurring organic growth in H2 2026 and into 2027, driven by strong renewal rates and new product sales. Post-LS&H divestiture, the recurring revenue mix will increase to approximately 92%, enhancing predictability.
Significant investment in AI is yielding tangible results, with new AI-native products like Web of Science Research Intelligence generating a multimillion-dollar ACV pipeline and securing 77 paying customers. The introduction of Nexus Connect and IP-1, leveraging Clarivate's proprietary datasets, demonstrates a strong innovation roadmap aimed at creating new revenue streams and embedding intelligence into customer workflows.
The agreement to sell the Life Sciences & Healthcare segment sharpens Clarivate's strategic focus on its higher-growth Academia & Government and Intellectual Property segments. Proceeds from the divestiture, combined with robust free cash flow, will be used to reduce debt by approximately $900 million this year, strengthening the balance sheet and enhancing financial flexibility.
Bear case
Clarivate continues to face headwinds in transactional revenues, which contributed to a $9 million decline in overall organic revenues in Q2 2026 and are expected to be down slightly year-over-year for the full year. While partly due to strategic shifts to subscriptions, lumpiness in certain areas and the divestiture of transactional heavy businesses could temper overall revenue growth.
While the Life Sciences & Healthcare divestiture agreement is in place, the closing is pending regulatory approvals, introducing execution risk. Furthermore, the full-year free cash flow guidance is now at the low end of the range due to approximately $70 million in one-time transaction and restructuring costs associated with the divestiture, impacting immediate cash flow generation.
Despite Clarivate's AI innovation, the broader industry is rapidly adopting AI, including major LLM providers. The trend of larger customers wanting to embed Clarivate's proprietary data into their own corporate AI products (MCP capabilities) could challenge direct Clarivate platform adoption and pricing power if not managed effectively, potentially impacting differentiation and growth acceleration.
Bull / Bear Case
- Bear Case
- Clarivate continues to face headwinds from declining transactional revenues, which contributed to a $9 million organic revenue decline in Q2 2026 and are expected to be down slightly for the full year. While strategic, the Life Sciences & Healthcare divestiture carries execution risk, including pending regulatory approvals, and the full-year free cash flow guidance is now at the low end of the range due to approximately $70 million in one-time transaction and restructuring costs. Despite Clarivate's AI innovation, the broader industry's rapid AI adoption and the trend of larger customers embedding Clarivate's proprietary data into their *own* corporate AI products could challenge direct platform adoption, pricing power, and differentiation. The stock's significant underperformance post-earnings suggests market skepticism regarding the pace of growth acceleration and the immediate impact of one-time costs.
- Bull Case
- Clarivate is effectively executing its Value Creation Plan, driving sequential improvement in recurring organic growth and significant adjusted EBITDA margin expansion. Q2 2026 organic ACV growth improved to 1.5% and profit margin expanded to over 42%. The company expects further acceleration in recurring organic growth in H2 2026 and into 2027, bolstered by strong renewal rates and new product sales. The divestiture of the Life Sciences & Healthcare segment will increase the recurring revenue mix to approximately 92%, enhancing predictability and strategic focus on the higher-growth Academia & Government and Intellectual Property segments. Significant AI investments are yielding tangible results with new AI-native products like Web of Science Research Intelligence generating a multimillion-dollar ACV pipeline and IP-1 in development. Proceeds from the divestiture, combined with robust free cash flow, are slated to reduce debt by approximately $900 million this year, strengthening the balance sheet and enhancing financial flexibility for long-term shareholder value creation.
- More Compelling & Why
- Bear. The stock's significant underperformance post-earnings (-17.50% vs. SPY's 0.83%) suggests the market is heavily discounting the bullish narrative. While the company projects improved recurring organic growth, the immediate impact of $70 million in one-time transaction and restructuring costs pushing free cash flow to the low end of guidance, coupled with persistent transactional revenue headwinds, makes the near-term outlook challenging. The market appears to be valuing CLVT based on its current, somewhat muted, organic growth and the immediate FCF impact, rather than the promised acceleration. My view would flip if Clarivate consistently beats its organic ACV growth targets (especially in IP) and demonstrates a clear path to significantly improved free cash flow generation *after* the one-time costs, leading to a more attractive FCF yield.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Organic Annual Contract Value (ACV) Growth Acceleration (Excluding LS&H) | Accelerating organic ACV growth, particularly in the core Academia & Government (A&G) and Intellectual Property (IP) segments, is crucial for future recurring revenue predictability, validating the Value Creation Plan, and demonstrating successful adoption of new AI-driven products, especially given recent market skepticism. | Management's commentary on ACV trends in Q3 2026, specifically progress towards A&G approaching 3% growth and IP returning to growth by year-end, blending to about 2.25% growth for the full year. | Bullish: Management indicates ACV growth is on track or exceeding the blended 2.25% full-year target, with strong contributions from A&G and IP. Bearish: Management signals challenges in achieving the targeted ACV acceleration, particularly in the IP segment's return to growth, or a downward revision of the full-year blended target. | Clarivate's Q3 2026 earnings call transcript and presentation (expected late October/early November 2026). | Industry reports on academic research and IP software adoption trends. | Thinknum: Job postings for sales/account management roles at Clarivate (indicating sales intensity). |
| Adjusted EBITDA Margin Expansion and Cost Discipline | Continued expansion of Adjusted EBITDA margin demonstrates the success of Clarivate's Value Creation Plan, driven by disciplined cost management, AI-enabled efficiencies, and the strategic disposals, which are crucial for profitability and free cash flow generation. | Q3 2026 Adjusted EBITDA margin and management's reaffirmation or revision of the full-year target of nearly 43%. Commentary on cost efficiencies offsetting inflation and the impact of strategic disposals. | Bullish: Q3 2026 Adjusted EBITDA margin shows continued year-over-year expansion, aligning with or exceeding the full-year guidance of nearly 43%. Bearish: Adjusted EBITDA margin expansion slows or reverses in Q3 2026, or management indicates challenges in achieving cost savings. | Clarivate's Q3 2026 earnings call transcript and presentation (expected late October/early November 2026). | Company news releases regarding internal efficiency initiatives or restructuring. | S&P Global Market Intelligence: Consensus analyst estimates for EBITDA margin. |
| Intellectual Property (IP) Segment Recurring Organic Revenue Return to Growth | The IP segment's return to positive recurring organic revenue growth is critical for overall company growth acceleration, demonstrating the effectiveness of new leadership (Simon Webster), AI innovation (IP-1, RiskMark), and improved commercial intensity in a key market. | Q3 2026 earnings report for specific organic recurring revenue growth figures for the IP segment. Management commentary on the impact of Simon Webster's leadership and new AI products like IP-1. | Bullish: IP segment reports positive recurring organic revenue growth in Q3 2026, or management provides strong forward-looking indicators for H2 2026. Bearish: IP segment's recurring organic revenue remains flat or declines in Q3 2026, or management expresses caution about H2 growth targets. | Clarivate's Q3 2026 earnings call transcript and presentation (expected late October/early November 2026). | Google Trends: Search interest for "Derwent Innovation" or "RiskMark" (Clarivate IP products). | Apptopia/Similarweb: Web traffic and usage trends for Clarivate's IP platforms (e.g., Derwent Innovation). |
| New AI-Driven Product Adoption & Pipeline Growth | Successful adoption and pipeline generation from new AI-native products are crucial for accelerating organic growth, expanding Clarivate's market reach, and reinforcing its competitive position as an AI innovator leveraging proprietary datasets. | Management updates on the ACV pipeline generated by Web of Science Research Intelligence (currently "multimillion-dollar" with 77 paying customers), and progress in the development and early customer engagement for IP-1, including any new customer wins or pipeline figures. | Bullish: Management reports significant increases in the ACV pipeline and paying customers for Web of Science Research Intelligence, or positive early feedback and adoption metrics for IP-1. Bearish: Slow adoption or limited pipeline growth for new AI products, or delays in IP-1 development. | Clarivate's Q3 2026 earnings call transcript and presentation (expected late October/early November 2026), company press releases on product milestones. | Google Trends: Search interest for "Web of Science Research Intelligence" or "Clarivate IP-1". Academic/IP industry forums for discussions on new tools. | G2/Capterra: User reviews and sentiment for new Clarivate AI products. |
| Life Sciences & Healthcare (LS&H) Segment Divestiture Closing and Debt Reduction | The successful and timely closing of the LS&H divestiture for $600 million will simplify Clarivate's operating model, increase recurring revenue mix to approximately 92%, and provide significant proceeds for debt reduction, strengthening the balance sheet and enhancing financial flexibility. | Announcement of regulatory approvals and the definitive closing date of the LS&H divestiture by year-end 2026. Subsequent announcement of the specific amount of debt retired using the $600 million proceeds. | Bullish: Transaction closes by year-end 2026 as planned, with proceeds used to retire notes due in the next few years, contributing to the targeted $900 million debt reduction this year. Bearish: Delays in regulatory approvals or closing beyond year-end 2026, or a significant reduction in expected net proceeds. | Company press releases, SEC filings (8-K, 10-Q), investor relations section of Clarivate's website. | Financial news outlets (e.g., Reuters, Bloomberg) for M&A updates. | Dealogic: M&A transaction status updates. |
Key Reported Metrics, Reratings Triggers & ResultsAdjusted EBITDA reflects the company's operational efficiency and profitability. Its growth is essential for funding strategic initiatives, debt reduction, and
Upcoming print · 2026-11-04
| Key reported metrics | ||
|---|---|---|
| Metric | Last period | Why it matters |
| Adjusted EBITDA Growth | more than 42% (maintained over same period last year) | Adjusted EBITDA reflects the company's operational efficiency and profitability. Its growth is essential for funding strategic initiatives, debt reduction, and demonstrating the benefits of cost discipline and AI-enabled efficiencies to shareholders. |
| Intellectual Property (IP) Segment Recurring Organic Revenue Growth | 0% | The IP segment is a core focus post-divestiture, and its return to positive growth is crucial for overall organic acceleration and investor confidence, especially with new AI products and leadership changes aimed at turnaround. |
| Organic Annual Contract Value (ACV) Growth | 1.5% y/y | This metric is a key indicator of Clarivate's underlying business momentum and the success of its Value Creation Plan. Strong ACV growth validates the subscription-led strategy and enhances revenue predictability, crucial for investor confidence. |
Last reported · 2026-07-29
| Key reported metrics | Rerating thresholds | Earnings results | ||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date | Actual reported | Hit target? | Notes |
| Free Cash Flow (FCF) Generation | declined 28.4% | Hitting this FCF target is critical as it underpins Clarivate's aggressive debt reduction strategy, aiming to lower net leverage from 4x to ~2.5x. Robust FCF generation validates the Value Creation Plan, enhances financial flexibility, and demonstrates the company's capacity to fund strategic AI investments and deliver long-term shareholder value. | Free Cash Flow (FCF) generation in Q2 2026 needs to be strong, demonstrating a clear acceleration from Q1's $79 million and putting the company firmly on track to meet or exceed its full-year guidance of $400 million. This implies Q2 FCF significantly above $79 million, ideally showing a quarterly run-rate that supports the annual target, coupled with consistent progress in early debt retirement. | Hitting this FCF target is critical as it underpins Clarivate's aggressive debt reduction strategy, aiming to lower net leverage from 4x to ~2.5x. Robust FCF generation validates the Value Creation Plan, enhances financial flexibility, and demonstrates the company's capacity to fund strategic AI investments and deliver long-term shareholder value. | $44 million ($6 million lower than same period last year) | No | Free cash flow in Q2 was $44 million, which was lower than Q1's $79 million and $6 million lower than the prior year. This represents a deceleration, not an acceleration, and puts the full-year FCF guidance at the low end of the range due to transaction and restructuring costs related to the LS&H divestiture. | |
| Organic Annual Contract Value (ACV) Growth | 1.6% | Hitting this threshold matters because Organic ACV Growth is a key indicator of Clarivate's underlying business momentum and the success of its Value Creation Plan. Strong acceleration validates the subscription-led growth strategy, enhances revenue predictability, and builds investor confidence, which is crucial given recent negative analyst sentiment and revenue decline forecasts. It would signal effective execution and potential for long-term shareholder value. | Clarivate's Organic Annual Contract Value (ACV) Growth metric needs to accelerate significantly from its Q1 2026 value of 1.6%. To drive a rerating higher, it would likely need to hit at least 2.5% in Q2 2026, demonstrating strong progress towards the upper end of its full-year 2026 guidance of 2% to 3%. This would signal a clear beat on the expected acceleration and provide a positive surprise against the current cautious analyst sentiment, which has seen price target reductions and a "Hold" consensus. | Hitting this threshold matters because Organic ACV Growth is a key indicator of Clarivate's underlying business momentum and the success of its Value Creation Plan. Strong acceleration validates the subscription-led growth strategy, enhances revenue predictability, and builds investor confidence, which is crucial given recent negative analyst sentiment and revenue decline forecasts. It would signal effective execution and potential for long-term shareholder value. | 1.5% y/y | No | Organic ACV growth in Q2 improved to 1.5%, which is a slight deceleration from Q1's 1.6% and did not hit the rerating trigger of at least 2.5%. Management noted that Q2 results were in line with expectations, anticipating a pullback in recurring organic growth, and expects ACV to inflect in the second half of the year. The full-year organic ACV is now expected in the lower half of the 2-3% range, blending to about 2.25% growth, due to the LS&H divestiture. | |
| Adjusted EBITDA Margin | 4.8% | Achieving this significant margin expansion validates Clarivate's Value Creation Plan and AI-driven efficiencies, signaling improved operational profitability and robust free cash flow generation. This strengthens the investment thesis, supports aggressive debt reduction, and enhances shareholder value, driving a positive rerating. | For Clarivate Plc (CLVT) to rerate higher, its Adjusted EBITDA Margin in the Q2 2026 earnings report needs to demonstrate approximately 200 basis points of year-over-year expansion, aligning with or exceeding the company's full-year guidance of nearly 43%. | Achieving this significant margin expansion validates Clarivate's Value Creation Plan and AI-driven efficiencies, signaling improved operational profitability and robust free cash flow generation. This strengthens the investment thesis, supports aggressive debt reduction, and enhances shareholder value, driving a positive rerating. | more than 42% (maintained over same period last year) | No | The adjusted EBITDA margin expanded to more than 42% in Q2. However, the company stated that disciplined cost management allowed them to 'maintain our adjusted EBITDA margin over the same period last year,' implying negligible year-over-year expansion in Q2, missing the target of approximately 200 basis points of expansion. The full-year guidance for adjusted EBITDA margin remains at nearly 43%, with an expected expansion of about 200 bps, suggesting this expansion is anticipated in the second half of the year. | |
Key QuestionsWill Clarivate achieve its revised full-year organic ACV growth target of approximately 2.25%, driven by the anticipated sequential acceleration in recurring or
Will Clarivate achieve its revised full-year organic ACV growth target of approximately 2.25%, driven by the anticipated sequential acceleration in recurring organic growth in the second half of 2026, particularly in the Academia & Government and Intellectual Property segments?
- Question 2
Will the divestiture of the Life Sciences & Healthcare segment close by year-end 2026 as planned, and will the net proceeds effectively contribute to the targeted $900 million debt reduction, despite the anticipated transaction and restructuring costs impacting free cash flow?
- Question 3
How quickly will Clarivate's newly launched AI-native products, such as Web of Science Research Intelligence and IP-1, gain significant customer adoption and translate into material new revenue streams, thereby validating the company's AI innovation strategy and competitive differentiation?
Earnings Transcript Summary
· 2026Q2 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. Accelerating organic growth: Management emphasized that they have the building blocks in place to accelerate organic growth, driven by AI innovation, new product introductions like Web of Science Research Intelligence and IP-1, and improved commercial intensity. 2. Portfolio rationalization and deleveraging: The agreement to sell the Life Sciences & Healthcare segment is a key step in sharpening focus on core segments, improving the recurring revenue mix, and using net proceeds to reduce debt and strengthen the balance sheet. 3. Disciplined cost management and profitability: The company maintained disciplined cost management, expanded profit margins to over 42%, and expects continued margin expansion in the second half of the year, aiming for nearly 43% for the full year. | Call Takeaway & ToneThe overall takeaway of the call was positive and confident. Management reiterated that the Value Creation Plan is working, with key building blocks in place to accelerate organic growth and drive long-term shareholder value. The tone was optimistic, highlighting steady execution, successful AI innovation, strategic portfolio rationalization (LS&H divestiture), disciplined cost management, and a strengthened balance sheet, all contributing to expected sequential improvement in recurring organic growth in the second half of 2026 and continued momentum into 2027. | Prior Quarter'S Y/Y Growth By SegmentIn Q1 2026, overall organic ACV growth was 1.6% year-over-year. Academia & Government (A&G) organic ACV growth was 2%. Intellectual Property (IP) organic ACV trends improved to nearly flat year-over-year. Life Science & Health (LS&H) saw an almost 1% rise in organic revenue. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. Timing of renewals impacting ACV growth and persistence in the second half: Analysts questioned if timing around renewals impacted ACV growth and if this would persist. Management responded that Q2 results were in line with expectations, with strong renewal rates and good opportunities for new products. They do not believe it's an elongation of the renewal cycle and expect ACV and organic recurring revenue to inflect in the second half, with good line of sight for A&G's business already secured. 2. The MCP (Multi-Cloud Platform) opportunity, client types, growth contribution, and pricing: Analysts asked about the MCP opportunity. Management explained their AI innovation focuses on both AI-enabled existing products and new AI-native products (like Nexus Connect and IP-1) that create new revenue streams. They noted that bigger customers want to embed Clarivate's proprietary data into their corporate AI products (MCP capabilities), while smaller customers may use it in Clarivate's environment, indicating early but promising momentum. 3. Expectation for acceleration of organic growth, particularly between Academia & Government and IP, and the outlook for 2027: Analysts sought more detail on the expected acceleration. Management expressed optimism for both segments, citing momentum in IP with recurring revenue returning to flat in Q2 and expected growth in H2, bolstered by Simon Webster rejoining as president of the IP segment and new AI innovations like IP-1. A&G's momentum is also building with new products like Web of Science Research Intelligence. 4. Transactional revenue performance, including industry versus idiosyncratic factors and the path to improvement: Analysts inquired about the decline in transactional revenue. Management stated that moving away from transactional business is part of their Value Creation Plan, including divesting certain businesses and transforming others to subscription. They acknowledged headwinds in LS&H transactional revenue in Q2 and some lumpiness in other segments, but expect improvement in the second half and a slight full-year decline in transactional revenue. | Revenue SegmentsOverall organic Annual Contract Value (ACV) growth improved to 1.5% year-over-year. Academia & Government (A&G) delivered 2% organic ACV growth. Life Sciences & Healthcare (LS&H) also delivered 2% organic ACV growth. The Intellectual Property (IP) segment's recurring organic revenue improved to flat in the quarter. Overall organic revenues declined by $9 million, as recurring growth of about 1.5% only partially offset lower transactional revenues. Strategic disposals reduced revenue by $24 million. |
· 2026Q1 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. Execution of the Value Creation Plan (VCP): Management consistently highlighted the VCP's success, noting it as the fifth consecutive quarter of improved performance, leading to better organic revenue growth, margin expansion, and free cash flow generation. 2. AI Innovation and Efficiency: Clarivate is intensifying investment in AI for both product innovation (e.g., AI assistants, agentic AI, ecosystem integrations like Anthropic Claude Enterprise and Nexus Connect) and internal cost efficiencies across go-to-market, technology, and corporate functions. 3. Portfolio Rationalization and Debt Reduction: The company is actively pursuing the sale of the Life Science & Healthcare business to sharpen strategic focus and maximize shareholder value. Concurrently, they are committed to using free cash flow for early debt retirement, aiming to significantly reduce net leverage. | Call Takeaway & ToneThe overall takeaway of the call was positive and confident. Management emphasized that their Value Creation Plan is working, evidenced by improved financial performance, accelerating organic growth, margin expansion, and strong free cash flow generation. The tone was optimistic, highlighting significant progress in shifting to a subscription-first model, leveraging AI for both innovation and efficiency, and strategically rationalizing the portfolio while aggressively reducing debt. | Prior Quarter'S Y/Y Growth By SegmentFor Q4 2025: Academia & Government (A&G) achieved 2% organic ACV growth. Intellectual Property (IP) had organic ACV growth of 1.8% for the full year 2025, also mentioned for Q4 2025, with organic re-occurring revenues declining 1.2% and organic transactional revenues declining 11.9%. For Life Science & Health (LS&H), specific organic revenue growth was not explicitly stated in the Q4 2025 summaries, but transactional revenues were impacted by divestitures and disposals. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. AI capabilities, customer traction, and efficiency benefits: Analysts inquired about the reception of new AI products and quantifiable efficiency gains. Management responded by detailing three waves of AI product innovation (AI assistants, agentic AI, ecosystem integrations) and highlighted measurable value for customers, such as a 30-60% decrease in manual work and quadrupling throughput. They also acknowledged internal AI efficiency opportunities across various functions, with plans to dimension these later in the year. 2. IP segment performance and outlook: Analysts asked about the continued sequential improvements in organic sales metrics for IP and expectations for future growth. Management reiterated Clarivate's market leadership in IP, highlighted a new management team, improved sales execution, and strong AI innovation momentum (e.g., brand image search). They expressed confidence in IP's return to future growth, noting improved renewal rates and an expectation for the patent renewal business to return to growth in the second half of the year. 3. Transactional revenue decline in Academia & Government (A&G): An analyst questioned the decline in transactional revenues, particularly in A&G, and what would be needed for a rebound. Management explained that the decline was expected and in line with full-year guidance, primarily due to the timing of software implementations in A&G and the ongoing migration from transactional to subscription sales in Life Sciences. They anticipate a slight full-year decline but see opportunities to improve the sales pipeline for software products next year. | Revenue SegmentsOverall organic ACV growth was 1.6% year-over-year. Subscription organic revenue growth was 1.7% year-over-year. Academia & Government (ANG) continued to be a strong engine for recurring revenue growth, with organic ACV growth of 2%. Intellectual Property (IP) organic ACV trends improved to nearly flat year-over-year. Life Science & Health (LS&H) saw an almost 1% rise in organic revenue during the first quarter. Transactional revenues were down a couple of percent year-over-year. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketClarivate launched Web of Science Research Intelligence globally, an AI-native platform for research strategy, impact, and funding, which has already generated a multimillion-dollar ACV pipeline and secured 77 paying customers to date. The company also introduced Nexus Connect, an AI-native gateway providing a single university connector with AI chat agents like ChatGPT and Claude, embedding Clarivate's proprietary intelligence into existing research workflows for the academic community and leading to new revenue streams. In the IP segment, Clarivate announced the development of IP-1, a unified AI platform combining purpose-built AI agents with proprietary assets and expertise to efficiently solve patent and trademark intelligence questions and simplify complex workflows. RiskMark, an existing product, was named the best AI tool for lawyers at the 2026 CODiE awards for its use of predictive and generative AI to reduce trademark risk assessment from hours to minutes. Clarivate sees AI enablement of its existing products as a source for revenue from new logos, new products, and new returns, improving retention and allowing for AI-specific pricing for new products. Bigger customers are showing a tendency to embed Clarivate's proprietary data and capabilities (MCP capabilities) into their corporate AI products, while smaller customers may prefer to use it within Clarivate's environment. | About CompetitionClarivate differentiates itself in the industry by its ability to apply AI to highly curated proprietary datasets built and refined over decades. The company believes this reinforces its competitive position. In the IP business, Clarivate highlights its meaningful differentiators: scale, trusted relationships with leading law firms and blue-chip corporate IP teams, a strong recurring annuity and renewal engine, and differentiated proprietary content. Matti Shem Tov stated that Clarivate is taking a different route to disrupt the market using both its agentic capabilities and expertise and its proprietary data. | About The Broader IndustryThe company is strategically moving away from transactional revenue, a part of its Value Creation Plan (VCP), by divesting certain businesses and transforming remaining transactional portions into subscription models. There is an observed industry trend where larger customers prefer to embed proprietary data and AI capabilities into their own corporate AI products, integrating with generic LLMs like ChatGPT and Claude. | Where Things Are HeadedClarivate expects continued progress in shifting from transactional to recurring revenue in the coming quarters, focusing on subscription revenue. The Intellectual Property segment is anticipated to return to growth in the second half of the year. The company believes it is on a path towards accelerating its growth rate over the next couple of years. With the sale of the Life Sciences & Healthcare segment, Clarivate expects sequential improvement in recurring organic growth in the second half of 2026 and continued momentum into 2027. Organic annual contract value (ACV) is now expected in the lower half of the range due to the LS&H segment being moved to discontinued operations, but Academia & Government is expected to approach 3% growth and IP to return to growth by year-end, blending to about 2.25% growth. Recurring organic growth is still expected around 1.5%, an improvement of nearly a percentage point over last year. Revenue is projected just below the midpoint of the range at $2.35 billion due to foreign exchange, with organic recurring revenue mix increasing to approximately 92%. Adjusted EBITDA should remain over $1 billion, with a profit margin of nearly 43%, and adjusted diluted EPS is expected to grow about 9% to $0.75. Free cash flow is likely to be at the low end of the range due to transaction and restructuring costs related to the LS&H divestiture. Adjusted EBITDA margin is expected to expand by about 200 bps, driven by organic growth, cost discipline, and strategic disposals. Organic growth is anticipated to be about 1%, led by subscription revenue growth. The business is expected to accelerate organically in the second half, with profit margins inflecting due to growth, cost efficiencies, and disposals. Revenue is seasonally lower in Q3 and higher in Q4 due to patent and trademark renewals and transactional revenues. Free cash flow and LS&H divestiture proceeds will be used to reduce debt in the next few years. | Updates On ThemeLegal | Broader Themes EmergingThe acceleration of AI innovation and its application across products and operations is a significant emerging theme. The strategic shift from transactional to recurring subscription-based revenue models is a key business model optimization trend. Deleveraging and strengthening the balance sheet through strategic divestitures and debt reduction are prominent financial themes. | Bullish-Leaning Quotes (Short)We are delivering on our commitment and now we have the building blocks in place to accelerate organic growth. Organic ACV growth improved to 1.5% and profit margin has expanded to more than 42%. We believe that we are on a path towards accelerating our growth rate over the next couple of years. This transaction creates a more focused company as a subscription-first provider. We expect sequential improvement in recurring organic growth in the second half of 2026 and continued momentum into 2027. We are more confident than ever in our ability to execute, accelerate organic growth and deliver long-term value to shareholders. Adjusted EBITDA should remain at just over $1 billion for a profit margin of nearly 43%. We still expect adjusted diluted EPS will grow about 9% at the midpoint of the range to $0.75. We do believe IP will be turned around faster with Simon in place. Optimistic on both sides. | Bearish-Leaning Quotes (Short)The second quarter net loss was $269 million. Organic revenues declined by $9 million as recurring growth of about 1.5% only partially offset lower transactional revenues. We experienced an adjusted EBITDA headwind of $7 million due to the appreciation of a basket of foreign currencies. Free cash flow was $44 million in the second quarter, which was $6 million lower than the same period last year. Free cash flow is now likely to be at the low end of the range as we have contemplated the full transaction cost to close the LS&H divestiture. Transactional will be down slightly year-over-year. | HiringIn June, Clarivate welcomed Simon Webster as president of its IP segment. Michael Easton has been appointed as the next chief financial officer, effective August 8. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketClarivate is expanding its China footprint, securing a multiproduct institutional deal with Fuyao University, a new research-oriented university in China. The company is also expanding its IT professionals' ability to uncover insights, assess risk, and make faster, more confident decisions at a global scale through enhancements like Brand Image Search. Furthermore, Clarivate is extending the reach and relevance of its content across the broader AI ecosystem through strategic partnerships, such as integrating Cortellis regulatory intelligence with Anthropic Cloude Enterprise. | About CompetitionClarivate perceives itself as an AI innovator, with outside recognition as a 'fund leader in terms of AI innovation in the academic ecosystem'. The company sees great adoption for its AI products across its three segments and aims to 'set the scene as opposed to look at our competition'. In the patent renewal business, Clarivate's team has done a very good job on sales execution, 'improving our competitive position in that part of the market'. | About The Broader IndustryThe broader industry is seeing a significant shift towards the consumption of AI through major LLM providers by students, researchers, life science scientists, and IT professionals. There's also an observed improvement in patent stock growth over the last few years, which is considered a good leading indicator for the intellectual property market. | Where Things Are HeadedClarivate expects its organic annual contract value growth to continue in 2026, anticipating an increase of between 2% and 3%. The company projects adjusted EBITDA margin to expand by approximately 200 basis points, driven by a return to organic growth, continued cost discipline, and completing disposals. Free cash flow is expected to grow by about 10% to $400 million at the midpoint of the range. Clarivate plans to use its free cash flow for debt reduction, aiming to retire its secured notes entirely before their July 2028 maturity and then begin retiring the 2029 notes. The potential sale of the Life Science & Healthcare business is ongoing and, if materialized, is expected to eliminate the need for future bond refinancing. | Updates On ThemeEducation, | Broader Themes EmergingAI innovation and its application for both internal cost efficiencies and external product development is a significant emerging theme. | Bullish-Leaning Quotes (Short)This is our fifth consecutive quarter of improved performance. Our first quarter financial results have us on pace to achieve our full year guidance. Adjusted EBITDA was $241 million, representing a 41% margin, up almost 200 basis points year-over-year. Most important, the value creation plan is working. Academia & Government continue to be a strong engine for recurring revenue growth. We are confident in the return for IP back to future growth. Free cash flow is expected to grow by about 10% to $400 million at the midpoint of the range. | Bearish-Leaning Quotes (Short)First half of this year due to the comps and some timing from the first half of last year will be down slightly. Our guidance does contemplate that the transactional business will be down slightly compared to the prior year. If the potential sale does materialize, we expect it would eliminate the need for a future bond refinancing. | HiringClarivate is leveraging AI across corporate functions, including finance, human resources, and legal, to automate workflows and drive scalable efficiencies. The deployment of digital agents is expected to reduce manual effort, improve accuracy, and create operating leverage. For customers, Clarivate Academic AI solutions are optimizing library workflows, resulting in a 30% to 60% decrease in manual repetitive work and doubling or even quadrupling throughput, effectively reducing the need for manpower. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketClarivate is expanding its China footprint, securing a multiproduct institutional deal with Fuyao University, a new research-oriented university in China. The company is also expanding IT professionals' ability to uncover insights, assess risk, and make faster, more confident decisions at a global scale through enhancements like Brand Image Search. Furthermore, Clarivate is extending the reach and relevance of its content across the broader AI ecosystem through strategic partnerships, such as integrating Cortellis regulatory intelligence with Anthropic Cloude Enterprise. Nexus Connect is a new offering from Academia & Government that brings Clarivate's and other content into designated LLMs like ChatGPT and Copilot, making it very close to customers. The company won a new top 20 global pharmaceutical customer for DRG Fusion, its new real-world data analytics platform, and secured six-figure subscription wins with a biotech company for OpEx, demonstrating continued momentum across customer sizes and use cases. | About CompetitionClarivate perceives itself as an AI innovator, with outside recognition as a 'fund leader in terms of AI innovation in the academic ecosystem'. The company sees great adoption for its AI products across its three segments and aims to 'set the scene as opposed to look at our competition'. In the patent renewal business, Clarivate's team has done a very good job on sales execution, 'improving our competitive position in that part of the market'. Clarivate also states it is the market leader in IP and the only company with all three or four sub-offerings in IP. | About The Broader IndustryThe broader industry is seeing a significant shift towards the consumption of AI through major LLM providers by students, researchers, life science scientists, and IT professionals. There's also an observed improvement in patent stock growth over the last few years, which is considered a good leading indicator for the intellectual property market. | Where Things Are HeadedClarivate expects its organic annual contract value growth to continue in 2026, anticipating an increase of between 2% and 3%. The company projects adjusted EBITDA margin to expand by approximately 200 basis points, driven by a return to organic growth, continued cost discipline, and completing disposals. Free cash flow is expected to grow by about 10% to $400 million at the midpoint of the range. Clarivate plans to use its free cash flow for debt reduction, aiming to retire its secured notes entirely before their July 2028 maturity and then begin retiring the 2029 notes. The potential sale of the Life Science & Healthcare business is ongoing and, if materialized, is expected to eliminate the need for future bond refinancing. | Updates On ThemeLegal | Broader Themes EmergingAI innovation and its application for both internal cost efficiencies and external product development is a significant emerging theme. | Bullish-Leaning Quotes (Short)This is our fifth consecutive quarter of improved performance. Our first quarter financial results have us on pace to achieve our full year guidance. Adjusted EBITDA was $241 million, representing a 41% margin, up almost 200 basis points year-over-year. Most important, the value creation plan is working. Academia & Government continue to be a strong engine for recurring revenue growth. We are confident in the return for IP back to future growth. Free cash flow is expected to grow by about 10% to $400 million at the midpoint of the range. | Bearish-Leaning Quotes (Short)First half of this year due to the comps and some timing from the first half of last year will be down slightly. Our guidance does contemplate that the transactional business will be down slightly compared to the prior year. | HiringWithin corporate functions, Clarivate is leveraging AI across finance, human resources, and legal functions to automate workflows and drive scalable efficiencies, expecting the deployment of digital agents to reduce manual effort, improve accuracy, and create operating leverage. |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| CLVT_53166400 | by the end of the year | 2026-10-01 | 2026-12-31 | Closing of the Life Sciences & Healthcare segment divestiture. | This transaction will sharpen Clarivate's focus on core segments, improve the recurring revenue mix, and provide proceeds for debt reduction, enhancing financial flexibility. | Ticker | 2026-07-29 | earnings_transcript |